Abstract

Hypertriglyceridemia is an independent risk factor for coronary artery disease. Lipoprotein lipase (LPL) plays an essential role in the metabolism of triglyceride-rich lipoproteins (TRLs). Angiopoietin-like proteins ANGPTL3 and ANGPTL8 are shown to be important regulators of LPL activity. Increased concentrations of these proteins may reflect cardiovascular risk, and the treatment of patients with dyslipidemia with ANGPTLs inhibitors may decrease this risk. We assessed the gender-specific relationships of serum ANGPTL3 and ANGPTL8 with atherogenic lipid biomarkers and obesity in non-diabetic adults. The study comprised 238 participants aged 25–74 [122 with triglycerides (TG) <150 mg/dL (<1.7 mmol/L) and 116 with hypertriglyceridemia]. Total cholesterol, HDL-cholesterol, LDL-cholesterol, TG, C-reactive protein (CRP), glycated hemoglobin, apolipoprotein B, small dense LDL-C (sd-LDL-C), ANGPTL3, and ANGPTL8 were measured. Non-HDL-cholesterol, remnant cholesterol (remnant-C) concentrations, and body mass index (BMI) were calculated. Results: Women and men did not differ in terms of age, CRP levels, the percentage of obese subjects, and concentrations of atherogenic lipid biomarkers, except higher TG in males and higher ANGPTL3 concentrations in females. Positive correlations of both ANGPTLs with TG, remnant-C, and sdLDL-C levels were found in females. In males, only ANGPTL3 correlated positively with atherogenic biomarkers, but there were no correlations with ANGPTL8. Concentrations of ANGPTL3 were higher in obese men, whereas ANGPTL8 levels were higher in obese women. In women alone, ANGPTL8 showed very good discrimination power to identify subjects with hypertriglyceridemia (AUC = 0.83). Contrary to this, ANGPTL3 was a better discriminator of hypertriglyceridemia (AUC = 0.78) in male subjects. Regression models, adjusted for age, sex, and BMI showed a weak but significant effect of ANGPTL8 to increase the risk of hypertriglyceridemia. Conclusions: In females, ANGPTL8 is more strongly associated with TRLs metabolism, whereas in males, ANGPTL3 plays a more important role. We suggest sex differences be taken into consideration when applying new therapies with angiopoietin-like proteins inhibitors in the treatment of dyslipidemia.

Highlights

  • The most common cause of cardiovascular diseases (CVDs) is coronary atherosclerosis and risk factors for the occurrence of CVDs include dyslipidemia, hypertension, obesity, diabetes, smoking, and limited levels of physical activity

  • ANGPTL3 activity is enhanced by ANGPTL8 which interacts with ANGPTL3 by forming a complex increasing the inhibitory effect on Lipoprotein lipase (LPL) [4]

  • The median value of ANGPTL3 was significantly higher in females than in males, though that of ANGPTL8 was comparable

Read more

Summary

Introduction

The most common cause of cardiovascular diseases (CVDs) is coronary atherosclerosis and risk factors for the occurrence of CVDs include dyslipidemia, hypertension, obesity, diabetes, smoking, and limited levels of physical activity. Increased level of LDL-cholesterol is an important risk factor for the development of atherosclerosis, but high levels of triglyceride-rich lipoproteins (TRLs) contribute to atherosclerotic cardiovascular disease (ASCVD) [1]. Increased triglyceride (TG) levels may reflect increased levels of cholesterol in TRLs. Elevation of TG in the circulation is mostly caused by diabetes and obesity, but genetic factors may contribute. ANGPTL3 was shown to regulate circulating TG levels by inhibiting LPL activity and participating in the metabolism of cholesterol [2,3]. Observational studies have shown that increased concentrations of these proteins may reflect cardiovascular risk and suggest that treatment of patients with dyslipidemia with ANGPTL3 inhibitors may decrease the CVD risk [6–8]. We aimed to assess the gender-specific relationships of serum ANGPTL3 and ANGPTL8 with biomarkers of atherogenic lipid profile and obesity in non-diabetic adults

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call